SCHEMBL4861647

SCHEMBL4861647

CCc1ccc(Cc2c(O)nn(C3CCC3)c2C(F)(F)F)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 4/20 0.32
MAPT P10636 2/20 0.32
SLC5A2 P31639 2/20 0.32
PDE5A O76074 1/20 0.32
CETP P11597 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP2 O95551 1/20 0.31
GCGR P47871 2/20 0.31
KDM4E B2RXH2 2/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2042541 0.81 SLC5A2 (0.30) SLC5A2
SCHEMBL2045618 0.80 KDM4E (0.30) ALDH1A1MAPTKDM4EALOX15TSHR
SCHEMBL12589047 0.79 SLC5A2 (0.33) SLC5A2
SCHEMBL4860458 0.75 SLC5A2 (0.32) SLC5A2
SCHEMBL14017835 0.75 SLC5A2 (0.40) SLC5A2
SCHEMBL10028737 0.75 SLC5A2 (0.49) SLC5A2CYP3A4
SCHEMBL2050092 0.74 MPO (0.39) ALDH1A1MAPTGCGRKDM4EALOX15
SCHEMBL3766942 0.74 SLC5A2 (0.62) SLC5A2
SCHEMBL796791 0.74 SLC5A2 (0.62) SLC5A2
SCHEMBL2048537 0.73 MPO (0.41) ALDH1A1MAPTGCGRKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7956041-B2 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide AJINOMOTO CO., INC. (JP) 2011-06-07 US disclosed
US-7956041-B2 antidiabetic mixture contains an inhibitor of renal glucose reabsorption and a hypoglycemic agent; controlling blood glucose level; tolbutamide, chlorpropamide, glibenclamide, glipizide, glimepiride, and gliclazide; metformin, phenformin and buformin; repaglinide, nateglinide and mitiglinide AJINOMOTO CO., INC. (JP) 2011-06-07 US disclosed
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 GLA 180/4885POLB 4315/4885ALDH1A1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.